Background: Uncontrolled type 2 diabetes mellitus (T2DM) is a major health problem characterized by chronic hyperglycemia and systemic inflammation, where Interleukin-1β (IL-1β) plays a key role in worsening insulin resistance. Diacerein, an IL-1β inhibitor, has shown potential to reduce inflammation and improve glycemic control. This study aimed to assess the efficacy of diacerein on IL-1β…